



COMPANY OVERVIEW

Synthetic Biologics, Inc. is a clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. Our lead clinical candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, *C. difficile* infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company is also advancing SYN-020, an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.

RECENT NEWS

Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients

Oct 2 2020, 7:00 AM EDT

STOCK OVERVIEW

Symbol	SYN
Exchange	NYSE American
Market Cap	7.06m
Last Price	\$0.362999
52-Week Range	\$0.2522 - \$0.75

10/23/2020 03:59 PM EDT

INVESTOR RELATIONS

Synthetic Biologics, Inc.
Investor Relations Department
T: (301) 417-4364
info@syntheticbiologics.com

MANAGEMENT TEAM

Steven Shallcross

Chief Executive Officer, Chief Financial Officer, Treasurer and Secretary, Director

Michael Kaleko, MD, PhD

Senior Vice President, Research & Development

Vince Wachter, PhD

Head of Corporate & Product Development

SYNTHETIC BIOLOGICS, INC.

9605 Medical Center Drive

Suite 270

Rockville, MD 20850

US

T: (301) 417-4364

<https://www.syntheticbiologics.com>

DISCLAIMER

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in the Company's industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements.